Ticlopidine

Ticlopidine (PCR 5332), an antithrombotic proagent, acts as an allosteric, noncompetitive inhibitor of CD39 with the IC50 of 81.7 μM. Ticlopidine blocks several NTPDase isoenzymes with IC50s of 170 μM and 149 μM for NTPDase2 and NTPDase3, respectively. Ticlopidine is an inhibitor of CYP2C19 human liver cytochrome. Ticlopidine inhibits CYP2C9 and CYP3A4 with IC50s of 26.0 and 32.3 μM, respectively.

Product Specifications

CAS Number

[55142-85-3]

Product Name Alternative

PCR 5332

UNSPSC

12352005

Hazard Statement

H302, H319

Target

Cytochrome P450; NTPDase

Type

Reference compound

Related Pathways

Immunology/Inflammation; Metabolic Enzyme/Protease

Applications

Neuroscience-Neuromodulation

Field of Research

Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/ticlopidine.html

Purity

99.74

Solubility

DMSO : ≥ 100 mg/mL

Smiles

ClC1=CC=CC=C1CN2CCC3=C(C=CS3)C2

Molecular Formula

C14H14ClNS

Molecular Weight

263.79

Precautions

H302, H319

References & Citations

[1]Laura Schäkel, et al. 2-Substituted thienotetrahydropyridine derivatives: Allosteric ectonucleotidase inhibitors. Arch Pharm (Weinheim) . 2021 Dec;354 (12) :e2100300.|[2]I.KRASLOVA1, et al. Ticlopidine-Induced Cholestatic Inflammatory Hepatitis: New Insights into Pathogenetic Mechanisms of Drug-Related Hepatotoxicity. |[3]Si-hyung Yang, et al. Effects of ticlopidine on pharmacokinetics of losartan and its main metabolite EXP-3174 in rats. Acta Pharmacol Sin. 2011 Jul;32 (7) :967-72.|[4]F Piovella, et al. The effect of Ticlopidine on human endothelial cells in culture. Thromb Res. 1984 Feb 1;33 (3) :323-32.